# SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future

> **NCT07735559** · NA · NOT_YET_RECRUITING · sponsor: **University Hospital, Montpellier** · enrollment: 6 (estimated)

## Conditions studied

- Regenerative Medicine
- Induced Pluripotent Stem Cells (iPSC) Production

## Interventions

- **PROCEDURE:** Blood Collection for iPSC Generation

## Key facts

- **NCT ID:** NCT07735559
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2027-11
- **Final completion:** 2028-02
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735559, "SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*